Antimicrobial susceptibility of viridans group streptococci

被引:39
作者
Tuohy, M [1 ]
Washington, JA [1 ]
机构
[1] Cleveland Clin Fdn, Clin Microbiol Sect, Cleveland, OH 44195 USA
关键词
D O I
10.1016/S0732-8893(97)00140-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A total of 68 viridans group streptococci, including 31 Streptococcus sanguis, 12 S. mitis, 3 S. salivarius, and 8 S. milleri from blood, and an additional 14 S. milleri from abscesses and normally sterile sites, were tested against penicillin, amoxicillin, cefazolin, ceftriaxone, meropenem, clindamycin, quinupristin/dalfopristin, rifampin, levofloxacin, ofloxacin, vancomycin, and gentamicin with the microdilution method. The susceptibility rates for S. sanguis were: penicillin, 74%; amoxicillin, 84%; ceftriaxone, 94%; clindamycin, 87%, and vancomycin, 100%. The susceptibility rates for S. mitis were: penicillin, 42%; amoxicillin, 67%; ceftriaxone, 58%; clindamycin, 100%; and vancomycin, 100%. The susceptibility rates for S. milleri were: penicillin, 100%, amoxicillin, 100%; ceftriaxone, 100%, clindamycin, 100%; and vancomycin, 100%. Two of the three isolates of S. salivarius were susceptible to penicillin, amoxicillin, and ceftriaxone; all were susceptible to clindamycin and vancomycin. Levofloxacin, quinupristin/dalfopristin, and rifampin were highly active against all isolates. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:277 / 280
页数:4
相关论文
共 15 条
[1]  
AVADA A, 1992, CLIN INFECT DIS, V15, P33
[2]   BACTEREMIA DUE TO VIRIDANS STREPTOCOCCUS IN NEUTROPENIC PATIENTS WITH CANCER - CLINICAL SPECTRUM AND RISK-FACTORS [J].
BOCHUD, PY ;
EGGIMAN, P ;
CALANDRA, T ;
VANMELLE, G ;
SAGHAFI, L ;
FRANCIOLI, P .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (01) :25-31
[3]   ANTI-MICROBIAL SUSCEPTIBILITIES OF SPECIES OF VIRIDANS STREPTOCOCCI [J].
BOURGAULT, AM ;
WILSON, WR ;
WASHINGTON, JA .
JOURNAL OF INFECTIOUS DISEASES, 1979, 140 (03) :316-321
[4]   BACTEREMIA DUE TO VIRIDANS STREPTOCOCCI THAT ARE HIGHLY RESISTANT TO PENICILLIN - INCREASE AMONG NEUTROPENIC PATIENTS WITH CANCER [J].
CARRATALA, J ;
ALCAIDE, F ;
FERNANDEZSEVILLA, A ;
CORBELLA, X ;
LINARES, J ;
GUDIOL, F .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (05) :1169-1173
[5]  
DAJANI AS, 1997, JAMA-J AM MED ASSOC, V277, P1764
[6]   Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States [J].
Doern, GV ;
Ferraro, MJ ;
Brueggemann, AB ;
Ruoff, KL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) :891-894
[7]   Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections [J].
Endtz, HP ;
Mouton, JW ;
denHollander, JG ;
vandenBraak, N ;
Verbrugh, HA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1146-1149
[8]   PREVALENCE OF PENICILLIN-RESISTANT VIRIDANS STREPTOCOCCI IN HEALTHY-CHILDREN AND IN PATIENTS WITH MALIGNANT HEMATOLOGICAL DISORDERS [J].
GUIOT, HFL ;
COREL, LJA ;
VOSSEN, JMJJ .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (08) :645-650
[9]   ACTIVITIES OF POTENTIAL THERAPEUTIC AND PROPHYLACTIC ANTIBIOTICS AGAINST BLOOD CULTURE ISOLATES OF VIRIDANS GROUP STREPTOCOCCI FROM NEUTROPENIC PATIENTS RECEIVING CIPROFLOXACIN [J].
MCWHINNEY, PHM ;
PATEL, S ;
WHILEY, RA ;
HARDIE, JM ;
GILLESPIE, SH ;
KIBBLER, CC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) :2493-2495
[10]  
National Committee for Clinical Laboratory Standards, 1997, METH DIL ANT SUSC TE